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Objectives The aim of this study was to evaluate the performance of the aortic regurgitation (AR)
index as a new hemodynamic parameter in an independent transcatheter aortic valve implantation
(TAVI) cohort and validate its application.
Background Increasing evidence associates more-than-mild periprosthetic aortic regurgitation
(periAR) with increased mortality and morbidity; therefore precise evaluation of periAR after TAVI is
essential. The AR index has been proposed recently as a simple and reproducible indicator for the
severity of periAR and predictor of associated mortality.
Methods The severity of periAR was evaluated by echocardiography, angiography, and periproce-
dural measurement of the dimensionless AR index  ([diastolic blood pressure  left ventricular
end-diastolic pressure]/systolic blood pressure)  100. A cutoff value of 25 was used to identify pa-
tients at risk.
Results One hundred twenty-two patients underwent TAVI by use of either the Medtronic Cor-
eValve (Medtronic, Minneapolis, Minnesota) (79.5%) or the Edwards-SAPIEN bioprosthesis (Edwards
Lifesciences, Irvine, California) (20.5%). The AR index decreased stepwise from 29.4  6.3 in patients
without periAR (n  26) to 28.0  8.5 with mild periAR (n  76), 19.6  7.6 with moderate periAR
(n  18), and 7.6  2.6 with severe periAR (n  2) (p  0.001). Patients with AR index 25 had a
signiﬁcantly increased 1-year mortality rate compared with patients with AR index 25 (42.3% vs.
14.3%; p  0.001). Even in patients with none/mild periAR, the 1-year mortality risk could be further
stratiﬁed by an AR index 25 (31.3% vs. 14.3%; p  0.04).
Conclusions The validity of the AR index could be conﬁrmed in this independent TAVI cohort and
provided prognostic information that was complementary to the severity of AR. (J Am Coll Cardiol
Intv 2012;5:858–65) © 2012 by the American College of Cardiology Foundation
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859With more than 50,000 implantations worldwide, trans-
catheter aortic valve implantation (TAVI) has increasingly
become an alternative treatment strategy for patients with
severe aortic stenosis regarded at high risk or inoperable by
open-heart surgery (1–10). However, significant concerns
are raised around the higher, mostly procedure-related
incidence of paravavular leakage. Because transcatheter
heart valves are implanted in a sutureless fashion using
oversizing to expand a stent at the level of the aortic
annulus, several etiologies can be invoked to explain
periprosthetic aortic regurgitation (periAR) after TAVI,
such as heavily calcified cusps, suboptimal placement of the
prosthesis, and/or annulus-prosthesis-size mismatch. Re-
cently published studies report an incidence of periAR in
more than 70% of all TAVI patients that are graded as
moderate/severe in approximately 10% to 28% of the
patients (1,2,4,5,8–17).
Because evidence is growing that more-than-mild periAR
after TAVI is associated with dramatically increased mortality
and morbidity, precise evaluation of aortic regurgitation (AR)
during the procedure is essential to take effective countermea-
sures but remains challenging, despite the recently published
Valve Academic Research Consortium (VARC) criteria (18–23).
ecently, the AR index as an objective hemodynamic param-
ter has been introduced for the precise assessment of the
everity of periAR during the TAVI procedure to take effective
ountermeasures, such as post-dilation, snaring, or valve-in-
alve implantation to decrease periAR if necessary (9).
The objective of this study was to evaluate the impact of
oderate/severe periAR and to validate the AR index on
utcome in an independent TAVI cohort.
ethods
Patient cohort. Between January 2007 and March 2011,
22 patients with severe aortic stenosis regarded at high risk
r inoperable by open-heart surgery underwent TAVI at
lenfield University Hospital in Leicester, United King-
om. Transcatheter aortic valve implantation patients
ere included in this prospective study, which complies
ith the Declaration of Helsinki and was approved by a
ocally appointed ethics committee, after written in-
ormed consent was obtained. Acceptance for TAVI
equired consensus by the multidisciplinary Heart Team.
atient screening, selection, and device implantation has
een described previously (24).
The TAVI was performed with the 3rd Generation 18-F
oreValve prosthesis (CoreValve Revalving Technology,
edtronic, Minneapolis, Minnesota) or the Edwards-
APIEN valve prosthesis (Edwards Lifesciences, Irvine,
alifornia). Annulus dimension was evaluated by trans-
sophageal echocardiography (TEE) and angiography. All
AVI procedures were performed under general anesthesiand echocardiographic control by TEE. After TAVI, sever- lty of periAR was assessed angiographically, echocardio-
raphically by TEE, and hemodynamically. Patients were
ollowed up in the outpatient clinic of the hospital. The
rimary endpoint of this study was all-cause mortality at 1
ear. Secondary endpoint was the occurrence of moderate/
evere periAR defined according to the definition of the
ARC (18). Information about the cause of death was
btained from the treating hospital or general practitioner.
Assessment of periAR. The occurrence and degree of
periAR was evaluated by angiography immediately after
valve deployment and by intraprocedural TEE/TTE with
an established integrative approach for semi-quantitative
grading according to the recently published VARC criteria
(18,19).
Simultaneous pressure measurements in the left ventricle
and in the ascending aorta were performed with fluid-filled
catheters before and after the procedure, in all patients.
All hemodynamic measurements
were averaged over 3 cardiac cy-
cles. The dimensionless AR index
was calculated retrospectively by
an independent cardiologist who
was unaware of the degree of
periAR and the clinical outcome,
according to the following for-
mula (9): ([diastolic blood pres-
sure (DBP)  left ventricular end-
diastolic pressure (LVEDP)]/
systolic blood pressure)  100.
Measurement of the prosthesis
implantation depth. The im-
plantation depth of the prosthe-
sis in the left ventricular outflow
tract was measured with the final
angiogram of the aorta with
consistent C-arm angulation
(perpendicular alignment of all 3
aortic cusps visible in the same plane before the TAVI
procedure). The depth of implantation was defined as the
distance from the native aortic annular margin on the side of
the non- and left-coronary cusp, respectively, to the most
proximal edge of the deployed stent-frame on the corre-
sponding side.
Statistical analysis. Statistical analyses were conducted with
BM SPSS Statistics (version 20.0.0, IBM Corporation,
omers, New York). Data are presented as mean  SD if
ormally distributed or as median and interquartile range if
ot normally distributed. Categorical variables are given as
requencies and percentages. Continuous variables were
ested for differences with the Student t test or the analysis
f variance test, when comparing more than 2 groups. For
ategorical variables, the chi-square test was used for further
nalysis. Pearson’s correlation coefficient was used to estab-
Abbreviations
and Acronyms
AR  aortic regurgitation
DBP  diastolic blood
pressure
EuroSCORE  European
system for cardiac operative
risk evaluation
LVEDP  left ventricular end-
diastolic pressure
periAR  periprosthetic
aortic regurgitation
TAVI  transcatheter aortic
valve implantation
TEE  transesophageal
echocardiography
VARC  Valve Academic
Research Consortiumish associations.
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860In the development cohort from Bonn, receiver operating
characteristic curve analysis was used to determine the cutoff
value for the AR index for the prediction of all-cause
mortality at 1 year (9). In our cohort, the cumulative survival
plot in relation to the severity of periAR and the AR index
cutoff value (25), respectively, was estimated by the
Kaplan-Meier method. Survival in groups was compared
with use of the log-rank test. To identify predictors of
1-year all-cause mortality after TAVI, a Cox proportional
hazard model was applied. All tests were 2-sided; statistical
significance was assumed when the null hypothesis could be
rejected at p  0.05.
Results
Baseline characteristics. In this study, 122 patients with
severe, symptomatic aortic stenosis at high risk for open-
heart surgery (age 81.7  6.8 years, Society of Thoracic
Surgeons mortality score: 7.3 4.3%, logistic EuroSCORE
22.4  13.0%) underwent TAVI by use of either the
Medtronic CoreValve (79.5%) or the Edwards-SAPIEN
prosthesis (20.5%). Baseline characteristics are summarized
in Table 1. Echocardiographic assessment of the severity of
periAR after TAVI demonstrated that moderate periAR
persisted in 18 patients (14.8%), and severe periAR per-
sisted in 2 patients (1.6%) despite correction maneuvers
(Fig. 1).
Because the occurrence of moderate/severe periAR was
considered clinically relevant, TAVI patients were divided
into 2 groups according to the severity of periAR (none/
mild vs. moderate/severe) for the comparison of baseline
characteristics. In patients with moderate/severe periAR,
both the logistic EuroSCORE (28.5  15.0% vs. 21.2 
12.2%; p  0.05) and the Society of Thoracic Surgeons
mortality score (9.5 4.4% vs. 6.8 4.1%; p 0.021) were
significantly higher compared with patients without or only
mild periAR. Furthermore, patients with moderate/severe
periAR after the procedure suffered more frequently from
previous myocardial infarction (40.0% vs. 9.8%; p  0.001)
and had a significantly lower left ventricular ejection fraction
(45.1  10.6% vs. 50.9  10.8%; p  0.029). The mean
aortic annulus diameter was significantly larger (23.8  1.6
mm vs. 22.7  1.9 mm; p  0.022), and the implantation
depth at the site of the left-coronary (12.5  5.0 mm vs.
8.8  3.9 mm; p  0.001) as well as of the noncoronary
cusp (11.0  4.5 mm vs. 8.1  4.1 mm; p  0.005) was
significantly lower in patients suffering from moderate/
severe periAR, compared with patients with none/mild
periAR. The cover index was significantly higher in patients
with none/mild periAR compared with patients with mod-
erate/severe periAR: 16.0  4.4% versus 13.5  3.6% (p 
0.020).
Treatment of periAR. Post-dilation of the valve prosthesisas performed in 12 of 27 patients with moderate/severeeriAR immediately after valve deployment. The final
ortogram after correction maneuvers showed that periAR
ould be reduced for at least 1 grade in 9 patients by
ost-dilation only. In 2 patients with severe periAR, a
econd prosthesis had to be implanted in “valve-in-valve
echnique” due to deep implantation (Fig. 1). Despite
ost-dilation, severe periAR remained unchanged in 2
noperable patients with heavily calcified cusps of the native
ortic valve.
Echocardiographic assessment of periAR. There were no
ases of more than trivial transvalvular AR. Transesophageal
chocardiography, which predominantly guided TAVI in
his cohort, revealed that 26 patients (21.3%) had no signs
f periAR, 76 patients (62.3%) had only mild periAR,
hereas 18 patients (14.8%) and 2 patients (1.6%) suffered
rom moderate and severe post-procedural periAR, respec-
ively—independent from the type of valve prosthesis. The
rading of periAR by TEE at the end of the TAVI
rocedure strongly correlated with the final angiogram after
alve deployment (r  0.80; p  0.001) (Fig. 2).
Hemodynamic assessment of periAR. Simultaneous mea-
urement of the left ventricular and aortic pressure showed
stepwise decrease of the gradient between LVEDP and
he DBP in the aorta with increasing degree of periAR (p
.001) immediately after valve implantation (Table 2).
To adjust the end-diastolic gradient for the systemic
lood pressure level, the AR index was calculated as pro-
osed recently in the Bonn cohort (9) according to the
ollowing formula: AR index ([DBP LVEDP]/systolic
lood pressure)  100. The AR index was 29.4  6.3 in
atients without periAR and decreased with increasing
everity of periAR from 25.1  6.4 in patients with mild
eriAR, to 16.8  5.3 in patients with moderate periAR,
nd to 4.3 1.4 in patients with severe periAR (p 0.001).
Clinical outcomes after TAVI according to the severity of
periAR. Of 122 patients, 11 (9.0%) died within the first 30
days after TAVI; 32 of 122 patients (26.2%) died during
follow-up of 1 year. Mean follow-up time in survivors was
672  444 days with a follow-up rate of 100%.
In patients with moderate/severe periAR as assessed by
post-procedural TEE, a 1-year mortality of 60.0% (12 of
20) was observed, compared with 19.6% (20 of 102) in
patients with none/mild periAR (p  0.001) (Fig. 3A). In
univariate regression analysis, moderate/severe periAR was
related to 1-year mortality after TAVI (hazard ratio 4.2,
95% confidence interval: 2.1 to 8.6; p  0.001) (Table 3).
AR index and outcome. An AR index of 25 could be
reconfirmed in this independent TAVI cohort as the opti-
mum cutoff value (with the maximum sum out of sensitivity
and specificity) for the prediction of moderate/severe
periAR (sensitivity 100%, specificity 68%; area under the
curve 0.89; p  0.001) and for the prediction of 1-year
mortality (sensitivity 73%, specificity 66%; area under the
curve 0.68; p  0.002). Patients with AR index 25 had a
peripros
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861significantly increased 1-year mortality risk compared with
patients with AR index 25 (43.3% vs. 14.3%: p  0.001)
(Fig. 3B).
As shown in the development cohort from Bonn (9), the
calculation of the AR index was particularly useful in
patients with none/mild periAR and provided complemen-
Table 1. Baseline Characteristics According to Degre
Assessed by TEE After the Procedure
All Patients
(N  122)
No
Age (yrs) 81.7 6.8
Male 65 (53.3)
Logistic EuroSCORE (%) 22.4 13.0
STS score: mortality (%) 7.3 4.3
Body mass index (kg/m2) 26.3 4.6
Height (cm) 165.6 10.5
Weight (kg) 72.3 15.1
Coronary artery disease 76 (62.3)
Peripheral artery disease 30 (24.6)
Previous MI 18 (14.8)
Previous PCI 34 (27.9)
Previous CABG 37 (30.3)
Previous stroke 20 (16.4)
Chronic renal failure 48 (39.3)
COPD 42 (34.4)
Pulmonary hypertension 17 (13.9)
LVEF (%) 49.9 10.9
Aortic valve area (cm2) 0.64 0.19
Mean aortic gradient (mm Hg) 44.2 15.8
Pre-procedural AR
None 60 (49.2)
Mild 51 (41.8)
Moderate 11 (9.0)
Severe 0 (0)
Aortic annulus diameter (mm) 22.9 1.9
Aortic annulus 26 mm 10 (8.2)
Balloon valvuloplasty size (mm) 23.0 1.8
Implantation depth NCC (mm) 8.6 4.3
Implantation depth LCC (mm) 9.4 4.3
Prosthesis type
CoreValve 26 mm 45 (36.9)
CoreValve 29 mm 52 (42.6)
Edwards-SAPIEN 23 mm 9 (7.4)
Edwards-SAPIEN 26 mm 16 (13.1)
Cover index (%)* 15.5 4.4
Access site
Transfemoral 119 (97.5)
Trans-subclavian 1 (0.8)
Transapical 2 (1.7)
Values aremean SD or n (%). *According to the definition of Détaint et
AR aortic regurgitation; CABG coronary artery bypass grafting;
fraction; EuroSCORE  European system for cardiac operative risk eva
noncoronary cusp; PCI percutaneous coronary intervention; periARtary prognostic information (p  0.04): in patients withnone/mild periAR, an AR index25 was related to a 1-year
mortality rate of 14.3% (10/70), whereas an AR index 25
was associated with a more than 2-fold higher 1-year
mortality rate of 31.3% (10 of 32), respectively. All patients
suffering from moderate/severe periAR after TAVI had an
AR index 25 associated with a very poor prognosis and a
eriprosthetic Regurgitation as
ild PeriAR
102)
Moderate/Severe PeriAR
(n  20) p Value
 6.9 82.5 6.1 0.57
(50.0) 14 (70.0) 0.11
 12.2 28.5 15.0 0.05
 4.1 9.5 4.4 0.012
 4.5 24.2 4.1 0.021
 10.3 166.7 11.2 0.62
 15.1 67.6 14.9 0.13
(58.8) 16 (80.0) 0.10
(22.5) 7 (35.0) 0.31
(9.8) 8 (40.0) 0.001
(25.5) 8 (40.0) 0.21
(30.4) 6 (30.0) 0.93
(13.7) 6 (30.0) 0.08
(37.3) 10 (50.0) 0.58
(31.4) 10 (50.0) 0.12
(11.8) 5 (25.0) 0.14
 10.8 45.1 10.6 0.029
 0.19 0.71 0.19 0.14
 16.4 38.0 11.2 0.11
0.16
(53.0) 6 (30.0)
(39.2) 11 (55.0)
(7.8) 3 (15.0)
(0) 0 (0)
 1.9 23.8 1.6 0.022
(5.9) 4 (20.0) 0.040
 1.9 23.5 1.6 0.28
 4.1 11.0 4.5 0.005
 3.9 12.5 5.0 0.001
0.20
(36.3) 8 (40.0)
(41.2) 10 (50.0)
(8.8) 0 (0)
(13.7) 2 (10.0)
 4.4 13.5 3.6 0.020
0.37
(98.0) 19 (95.0)
(1.0) 0 (0)
(1.0) 1 (5.0)
cover index (prosthesis size annulus diameter)/prosthesis size.
chronic obstructive pulmonary disease; LVEF left ventricular ejection
score; LCC  left-coronary cusp; MI  myocardial infarction; NCC 
thetic aortic regurgitation; STS Society of Thoracic Surgeons.e of P
ne/M
(n 
81.5
51
21.2
6.8
26.8
165.4
73.3
60
23
10
26
31
14
38
32
12
50.9
0.63
45.7
54
40
8
0
22.7
6
22.9
8.1
8.8
37
42
9
14
16.0
100
1
1
al. (14):
COPD
luationmortality rate of 60.0% (12 of 20) (Fig. 4).
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862Discussion
In this independent TAVI cohort, we were able to validate
the AR index as a new hemodynamic parameter for the
measurement of the degree of periAR and its predictive
Figure 1. Incidence and Severity of Periprosthetic Aortic Regurgitation
The prevalence of AR before and periprosthetic aortic regurgitation (periAR) a
sures. Absolute frequencies are given. BAV  balloon valvuloplasty; Snare  s
Figure 2. Assessment of the Degree of Periprosthetic
Aortic Regurgitation After TAVI by Angiography and Echocardiography
Incidence of periprosthetic aortic regurgitation after transcatheter aortic
valve implantation (TAVI) as assessed by angiography and transesophageal
echocardiography in accordance with Valve Academic Research Consortium
criteria.value for clinical outcome. This hemodynamic parameter
strongly predicted 1-year mortality after TAVI—independent
of the severity of periAR—and provided additional prog-
nostic information beyond the echocardiographically as-
sessed severity of periAR, because it was able to further
stratify TAVI patients with none or only mild periAR and
identified patients with increased risk for adverse outcome.
Occurrence of periAR after TAVI. In this validation cohort, it
as confirmed that severely impaired left ventricular ejec-
ion fraction, cover index as surrogate for prosthesis/annulus
ismatch (14), and prosthesis implantation depth are major
redictors for the occurrence of moderate/severe periAR
fter TAVI (9,12–16,23). The TAVI was performed under
eneral anesthesia and guided by intraprocedural TEE. In
ontrast, in the development cohort from Bonn, most of the
AVI procedures were performed under local anesthesia
nd predominantly guided by angiography and hemody-
amic parameters. Furthermore, patients from the Bonn
ohort underwent TAVI with use of the Medtronic Cor-
Valve prosthesis only, whereas in 20.5% of the patients in
he Leicester cohort, the Edwards-SAPIEN prosthesis was
sed. Interestingly, the incidence of moderate/severe
eriAR (Leicester: 16.4%, Bonn: 15.1%) was comparable
etween both cohorts. We observed a trend toward less
oderate/severe periAR in patients with use of the
dwards-SAPIEN prosthesis, although not significant
ompared with use of the Medtronic CoreValve prosthesis
8.0% vs. 18.8%; p 0.20). However, this subgroup analysis
is limited by the small sample size of Edwards-SAPIEN
nscatheter aortic valve implantation (TAVI) with the respective countermea-
atheter used; VIV  valve-in-valve implantation.fter trapatients in our cohort.
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863PeriAR and outcome after TAVI. Recent analyses underline
the importance of more-than-mild post-procedural periAR
for short- and long-term outcome (9,10,16). We were able
to confirm these findings in our cohort and demonstrated
that a moderate/severe periAR, which occurred in 15% to
16% of patients, was strongly related to both 30-day
(Leicester: 30.0%, Bonn: 22.7%) and 1-year mortality
(Leicester: 60.0%, Bonn: 63.6%). Interestingly, in our
TAVI cohort, patients suffering from moderate/severe
periAR (and subsequently worse short-term outcome) had a
significantly lower body mass index. This association might
be a potential confounder of—or at least partly contribute
to—the hypothesis that a low body mass index is an
independent predictor of mortality in TAVI patients (25).
Moderate periAR was tolerated in 15 patients without
corrective measures, which might be explained—at least in
Table 2. Hemodynamic Parameters After TAVI According to the Degree of
All Patients
(N  122)
No PeriAR
(n  27)
Aortic systolic pressure (mm Hg) 118.3 24.5 119.8 28.0
Aortic diastolic pressure (mm Hg) 49.1 9.8 51.9 8.6
LVEDP (mm Hg) 20.1 6.4 16.9 4.9
End-diastolic gradient (mm Hg) 29.1 9.7 35.2 7.8
AR index 24.6 7.6 29.4 6.3
Values are mean SD.
LVEDP left ventricular end-diastolic pressure; periAR periprosthetic aortic regurgitation; TAV
Figure 3. 1-Year Mortality According to the Severity of PeriAR and the Aor
Cumulative survival (freedom from all-cause mortality) according to the severit
echocardiography and aortic regurgitation index cutoff value (B) developed in the Bpart—by inclusion of early experience patients with under-
estimation of the negative impact of more-than-mild
periAR. However, the incidence of moderate/severe periAR
in our study cohort (16%) is in line with recently published
reports (between 10% and 28%) (8–17).
AR index and outcome. In addition, the AR index was a
trong predictor of 1-year mortality risk, even after adjustment for
he severity of periAR, indicating the independent relevance of
bjectively assessed hemodynamic changes in the long run.
Our data clearly underscore that all efforts must be taken
o avoid moderate/severe periAR in TAVI patients. In
atients with moderate/severe periAR after valve deploy-
ent, corrective measures—such as balloon valvuloplasty for
ot fully expanded stent frames, valve reposition with snare
atheters for too-deep implantation depth, or “valve-in
alve” technique for suboptimal deployment—play a crucial
osthetic Regurgitation
ild PeriAR
(n  75)
Moderate PeriAR
(n  18)
Severe PeriAR
(n  2) p Value
20.2 24.7 111.3 11.5 83.0 11.3 0.12
49.6 10.0 44.7 7.2 31.0 5.7 0.007
19.8 5.9 25.9 7.0 27.5 5.0 0.001
29.8 8.3 18.9 6.0 3.5 0.7 0.001
25.1 6.4 16.8 5.3 4.3 1.4 0.001
scatheter aortic valve implantation.
gurgitation Index
eriprosthetic aortic regurgitation (periAR) (A) as assessed by transesophagealPeripr
M
1tic Re
y of p
onn cohort (9). CI  conﬁdence interval; HR  hazard ratio.
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864role to decrease the severity of periAR and thereby increase
survival (9,13). We could demonstrate that the AR index is
a simple and reproducible hemodynamic measure for the
precise quantification of periAR and can guide periproce-
dural decision making.
Quantiﬁcation of periAR after TAVI. Because precise quanti-
fication of the degree of periAR remains challenging despite
the recently suggested VARC criteria—independent of
whether using a qualitative angiographic or semiquantitative
echocardiographic approach (11–13,18–22)—we are in
need of an objective parameter, such as the AR index. This
is especially applicable for the acute implantation situation
with sub-ideal conditions for echocardiographic examina-
tion, especially when the procedure is not performed under
general anesthesia, or in patients with chronic renal failure
with sparse use of contrast media. In both the development
cohort from Bonn and the validation cohort from Leicester,
we were able to demonstrate that the AR index as hemo-
dynamic parameter is easy to quantify and allows an
objective, fast, and reproducible assessment of the degree of
periAR directly during the procedure with the possibility to
undertake effective measures to decrease periAR and there-
fore increase survival.
Study limitations. The validity of the AR index could be
confirmed in this independent cohort of another high-
volume TAVI center, suggesting that this finding can be
generalized. Univariate regression analysis only has been
presented, because the event count was not sufficient to
support multivariate analysis with inclusion of all 7 mortal-
ity predictors in our study, and thus a multivariate model
would have been overfitted. However, an AR index below
the cutoff of 25 was an independent predictor for 1-year
mortality when multivariate Cox regression analysis was
performed. A prospective multicenter trial might be needed
to further verify these results. Furthermore, it has to be
tested whether our results apply to transcatheter heart valve
types other than the currently approved CoreValve or
Edwards-SAPIEN prosthesis.
Table 3. Univariate Cox Regression Analysis of the Association Between
Clinical Characteristics and 1-Year Mortality
HR (95% CI) p Value
Moderate/severe periAR 4.2 (2.1–8.6) 0.001
AR index cutoff value 3.5 (1.7–7.5) 0.001
STS score 10 2.9 (1.4–6.2) 0.005
Logistic EuroSCORE 20 2.8 (1.3–6.0) 0.006
Pulmonary hypertension 2.5 (1.1–5.6) 0.024
LVEF 35% 2.5 (1.1–5.7) 0.036
Chronic renal failure 2.2 (1.0–5.0) 0.05CI confidence interval; HR hazard ratio; other abbreviations as in Table 1.Conclusions
The AR index is strongly associated with periprosthetic AR
after TAVI, predicts 1-year mortality, and provides prog-
nostic information beyond the degree of AR as demon-
strated in this validation cohort.
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